Academic Journal
LGR5+ epithelial tumor stem-like cells generate a 3D-organoid model for ameloblastoma
| العنوان: | LGR5+ epithelial tumor stem-like cells generate a 3D-organoid model for ameloblastoma |
|---|---|
| المؤلفون: | Chang, Ting-Han, Shanti, Rabie M, Liang, Yanfang, Zeng, Jincheng, Shi, Shihong, Alawi, Faizan, Zhang, Qunzhou, Carrasco, Lee, Le, Ahn D |
| المصدر: | Article number 338 ; 546 ; 5 ; Departmental Papers (Dental) ; Cell Death and Disease ; true ; published ; 11 |
| سنة النشر: | 2020 |
| المجموعة: | University of Pennsylvania: ScholaryCommons@Penn |
| مصطلحات موضوعية: | Ameloblastoma, Animals, Carcinogenesis, Cell Line, Tumor, Cell Proliferation, Cell Self Renewal, Drug Resistance, Neoplasm, Epithelial Cells, Epithelial-Mesenchymal Transition, Male, Mice, Nude, Neoplastic Stem Cells, Organoids, Phenotype, Proto-Oncogene Proteins B-raf, Receptors, G-Protein-Coupled, Spheroids, Cellular, Thrombospondins, vemurafenib, B Raf kinase, BRAF protein, human, G protein coupled receptor, LGR5 protein, thrombospondin |
| الوصف: | Ameloblastoma (AM) is a benign but locally aggressive tumor with high recurrences. Currently, underlying pathophysiology remains elusive, and radical surgery remains the most definitive treatment with severe morbidities. We have recently reported that AM harbors a subpopulation of tumor epithelial stem-like cells (AM-EpiSCs). Herein, we explored whether LGR5+ epithelial cells in AM possess stem-like cell properties and their potential contribution to pathogenesis and recurrence of AM. We found that LGR5 and stem cell-related genes were co-expressed in a subpopulation of AM epithelial cells both in vivo and in vitro, which were enriched under 3D-spheroid culture. As compared to LGR5− counterparts, LGR5+ AM epithelial cells showed increased expression of various EMT- and stemness-related genes, and functionally, exhibited increased capacity to form 3D-spheroids and generate human tumor 3D organoids, which recapitulated the histopathologic features of distinct subtypes of solid AM, thus, contributing a useful human tumor platform for targeted therapeutic screening. Treatment with a selective BRAFV600E inhibitor, vemurafenib, unexpectedly enriched the subpopulation of LGR5+ AM-EpiSCs in tumor 3D organoids, which may have explained therapeutic resistances and recurrences. These findings suggest that LGR5+ AM-EpiSCs play a pivotal role in pathogenesis and progression of AM and targeted inhibition of both BRAF and LGR5 potentially serves a novel nonsurgical adjuvant therapeutic approach for this aggressively benign jaw tumor. © 2020, The Author(s). |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| Relation: | https://repository.upenn.edu/handle/20.500.14332/9292 |
| الاتاحة: | https://repository.upenn.edu/handle/20.500.14332/9292 https://hdl.handle.net/20.500.14332/9292 |
| رقم الانضمام: | edsbas.90C1207F |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |